BC 001

Drug Profile

BC 001

Alternative Names: BC001

Latest Information Update: 19 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Southern California
  • Developer NANTCANCERSTEMCELL
  • Class Antineoplastics
  • Mechanism of Action Hypoxia-inducible factor 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 19 Oct 2016 NantCancerStemCell plans a phase I trial for Solid tumours (Globavir pipeline, October 2016)
  • 09 Jul 2015 BC 001 licensed to Sorrento for Cancer
  • 09 Jul 2015 Preclinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top